In a large, multicenter US randomized clinical trial, investigators tested whether initiating a 7-day extended-release injectable buprenorphine formulation in the emergency department (ED) could improve...
A new retrospective claims analysis evaluated adherence to extended-release buprenorphine and its impact on healthcare resource utilization and cost among commercially insured patients with opioid use...
Nearly 108,000 Americans died of overdoses in 2022, surpassing the previous year’s record total, according to a CDC report. Although the official number of deaths caused by overdoses—107,941—breaks the...
Researchers examined the characteristics and trends related to the increased mortality rates associated with overdose in pregnant and postpartum women.
Researchers evaluated the use of opioid use disorder (OUD) medication prior to surgery in patients with OUD to determine whether the risk of overdose or complications are reduced. The findings of the study...
In a placebo-controlled, randomized trial, researchers tested the efficacy of cytisinicline—a smoking cessation medication—for those who would like to quit smoking.
The FDA approved the second over-the-counter nasal spray with the goal of increasing access to products that can rapidly reverse the effects of opioid overdose.
The FDA has approved a new buprenorphine treatment option for people with opioid use disorder following clinical trials that tested its safety and efficacy.
To guide prevention efforts for fatal poisonings in pediatric patients, the authors of a recent study examined characteristics of death from poisoning in young children within the United States.
